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Natural product and natural product-like molecules continue to be important for the devel-
opment of pharmaceutical agents, as molecules in this class play a vital role in the pipeline for
new therapeutics. Among these, tetracyclic terpenoids are privileged, with >100 being FDA-
approved drugs. Despite this signiﬁcant pharmaceutical success, there remain considerable
limitations to broad medicinal exploitation of the class due to lingering scientiﬁc challenges
associated with compound availability. Here, we report a concise asymmetric route to forging
natural and unnatural (enantiomeric) C19 and C20 tetracyclic terpenoid skeletons suitable to
drive medicinal exploration. While efforts have been focused on establishing the chemical
science, early investigations reveal that the emerging chemical technology can deliver
compositions of matter that are potent and selective agonists of the estrogen receptor beta,
and that are selectively cytotoxic in two different glioblastoma cell lines (U251 and U87).
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The means by which organic molecules can be synthesizedhas a profound impact on medicinal chemistry and drugdiscovery. Simply stated, without efﬁcient and ﬂexible
processes capable of preparing compositions of matter with drug-
like properties, medicinal chemistry programs cannot easily
materialize. While it is well appreciated that natural products are
a rich source of leads for drug discovery, it is also understood
that their molecular architectures are typically quite challenging
to address with de novo synthesis. In fact, organic chemistry to
enable broad investigation of structure–activity relationships
associated with medicinally relevant natural products is often not
available. This reality is one of the many factors that continue
to fuel developments in the ﬁeld of chemical synthesis, where
attention is directed at providing de novo means of producing
natural product and natural product-inspired agents with
increased efﬁciency and molecular ﬂexibility.
Of the vast classes of natural products known to possess
important biological and medicinal properties, perhaps none is
more proven as a source of therapeutics than tetracyclic terpe-
noids. This large class of molecules, including steroids and cardiac
glycosides, has had a transformative impact on our society
(Fig. 1a; C-18 and C-19 cores)1–6. Today, scores of such agents
are FDA-approved drugs used to treat a wide range of conditions,
and this success supports the conclusion that the basic molecular
skeleton associated with the class is a validated platform for drug
discovery and development.
Given this standing in medicinal chemistry, it is perhaps sur-
prising that tetracyclic terpenoids persist as signiﬁcant challenges
for de novo synthesis. While numerous achievements have
described synthetic forging of members of the broad class7–13,
and the scientiﬁc advances central to such triumphs in natural
product total synthesis have had a profound impact on the evo-
lution of organic chemistry as a discipline, it remains the case that
investigation of structure–activity relationships and production of
active pharmaceutical ingredients (APIs) based on tetracyclic
terpenoids typically proceed by derivatization of readily available
natural products (a synthesis activity otherwise known as semi-
synthesis)12.
This reality greatly constrains efforts aiming to investigate the
medicinal potential of diverse compositions of matter inspired by
this natural product class, and has likely contributed to the fact
that 100% of FDA-approved drugs in the area have the natural
absolute stereochemistry (the mirror image isomer observed in
nature). Accepting that the drug-like physical properties of a
molecule are not strictly dependent on absolute stereochemistry,
it appears as though a vast region of pharmaceutically relevant
chemical space has remained underexplored for decades14–17.
In nature, tetracyclic terpenoids possess a wide variety of
molecular skeletons that differ dramatically from the common
enantiodeﬁned C18 and C19 core skeletons of well-studied ster-
oid hormones (Fig. 1a). In fact, many subclasses of natural pro-
ducts in this area that have not been thoroughly investigated in
biology and medicine possess additional quaternary centers at C8,
C9, and C14, and display unique relative stereochemistry with
respect to each quaternary center.
Here, as summarized in Fig. 1b, c, a uniﬁed asymmetric entry
to tetracyclic systems related to the large and diverse class of
tetracyclic terpenoids is described. This chemical technology is
shown to be capable of accessing the euphane tetracyclic system,
while also delivering potent and selective agonists of the estrogen
receptor beta (ERβ).
Results
Design of the synthetic route. Studies began with recognition
that the challenges associated with enantioselective synthesis of
steroid hormones are distinct from those associated with highly
oxygenated and densely functionalized tetracyclic terpenoids that
possess widely varying substitution and stereochemistries (Fig. 2a,
b). Hoping to establish a uniﬁed theme capable of addressing the
key molecular challenges associated with a variety of tetracyclic
terpenoid skeletons (i.e., addressing the location and relative
stereochemistry of characteristic quaternary carbon centers), the
synthetic strategy depicted in Fig. 2c was conceived. Taking a
departure from previous studies aimed at the enantiospeciﬁc
synthesis of estranes18, it was thought that metallacycle-mediated
annulative cross-coupling19 between a readily available enyne (2)
and trimethylsilylpropyne 3 would deliver hydrindane inter-
mediate 4, possessing the C13 quaternary center common to this
large natural product class. Notably, and consistent with previous
studies, it was anticipated that 4 would be formed with high levels
of regioselectivity, positioning the trimethylsilyl (TMS) group at
C11 of the carbocyclic nucleus.
With hydrindane 4 in hand, it was thought possible to introduce
a C9 quaternary center simply by engaging the vinylsilane moiety in
initial acid-mediated protodesilylation, followed by a second
regioselective protonation of the diene to deliver a transient fully
substituted allylic cation intermediate (not depicted). Intramole-
cular regio- and stereoselective Friedel–Crafts alkylation was then
envisioned as a means to establish the fused tetracyclic skeleton 5—
a molecular composition that has structural features reminiscent of
numerous natural products (i.e., cayaponoside C2, Fig. 2b). Rather
than serving as a terminal intermediate of relevance for a relatively
small collection of terpenoid targets harboring a C9 quaternary
center, it was thought that this intermediate may also serve as a
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Fig. 1 Tetracyclic terpenoid skeletons and a means of synthesis from
epichlorohydrin. a The general skeleton of tetracyclic terpenoids (C18
through C20). b A uniﬁed enantiospeciﬁc route to a variety of tetracyclic
terpenoid motifs. c Application to the synthesis of a euphane-based
tetracyclic skeleton and the synthesis and discovery of a potent and
selective agonist of the estrogen receptor beta (ERβ)
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platform to access numerous other terpenoid skeletons. Speciﬁcally,
a sequence consisting of A-ring methyl ether cleavage followed by a
unique oxidative rearrangement marked by a 1,2-alkyl shift from
C9 to C10 was imagined to pave a path from 5 to the tetracyclic
system 6. Notably, this tetraene-containing product contains the
C10/C13 quaternary centers seen in numerous steroid hormones,
cardiac glycosides, limonoids, euphanes, and lanostanes (among
others).
While oxidative alkyl shift reactions have been described as a
means to convert phenols to dienones possessing a quaternary
center20–22, these reactions are typically conducted with sub-
strates that enable C–C bond formation through a semi-pinacol-
like process (substrates containing a benzylic tertiary alcohol),
where termination of the cationic rearrangement is coupled to the
formation of a ketone. The proposed process for conversion of 5
to 6 in Fig. 2c calls for migration of a methyl group from a
quaternary center, generation of a tertiary allylic cation, and
selective loss of a proton from C15 of the D-ring. Besides not
having strong precedent in support of this proposed molecular
transformation, at the outset of these studies methyl migration in
oxidative dearomatization chemistry was appreciated as being
notoriously problematic21,22.
Asymmetric synthesis of tetracyclic terpenoid skeletons. As
illustrated in Fig. 3a, epichlorohydrin (ent-1) was converted to
epoxide 7 by an established two-step procedure23, and subsequent
BF3•OEt2-promoted addition of an acetylide derived from 8
provided the stereodeﬁned substrate 9 in 85% yield. Regio- and
stereoselective annulative cross-coupling with TMS-propyne 3
then delivered hydrindane 10 in 70% yield as a single regio- and
stereoisomer19. Next, conditions were explored to accomplish the
desired tandem protodesilylation and cyclization reaction to form
the C9–C10 bond and establish the C9 quaternary center. As
illustrated in the highlighted table, treatment of 10 with BF3•OEt2
in nitromethane at 0 °C, converted the hydrindane intermediate
to the fully functionalized tetracycles 11 and 12. Here, cyclization
appeared to occur only at C9 of the intermediate allylic cation
(rather than at C14), with moderate selectivity for production of
the anti-isomer 11 (dr= 6:1; the major product possesses a
quaternary center at C9 that projects the methyl group on the
opposite face of the tetracycle as the preixisting group at C13).
In an effort to both enhance diastereoselection for this
cyclization and to alter the inherent facial preference for the
process, chiral Brønstead acids derived from complexation of
Binol to a Lewis acid were explored. This strategy was introduced
by Professor Yamamoto and further studied by Professor Corey
as a means to achieve enantioselective polyene cyclization
reactions24,25, and has to our knowledge not been investigated
for related double-asymmetric Friedel–Crafts type cyclization
chemistry. To establish a baseline for understanding simple
diastereoselection in this double-asymmetric annulation process,
an achiral system based on the combination of o,o’-dihydrox-
ybiphenyl•SnCl4 in CH2Cl2 at −78 °C was ﬁrst studied. Notably,
the selectivity for formation of the anti-isomer in this cyclization
reaction was increased to 9:1. Next, use of enantiodeﬁned Binols
in complex with SnCl4 or SbCl5 led to the discovery of a clear
double asymmetric relationship. In the mismatched case, use of
(R)-Binol•SbCl5 delivered the cyclized products as an 8:1 mixture
of anti-(11) and syn-(12) stereoisomers, and use of (R)-
Binol•SnCl4 resulted in production of the syn-isomer in
approximately an equal ratio with the anti-isomer (52%
combined yield).
In contrast, the matched case proved to be highly stereo-
selective. Treatment of 10 with (S)-Binol•SnCl4 delivered the
anti-isomer 11 in 50% yield with ≥ 20:1 stereoselectivity. Building
on the empirical model ﬁrst offered by Yamamoto24 for
enantioselective Brønstead acid-mediated polyene cyclization, it
is proposed that the relevant Binol•SnCl4 complex promotes
cyclization of substrates like 10 through an arrangement similar
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Fig. 2 Design of a synthesis strategy to access varied tetracyclic terpenoid skeletons. a Examples of steroid hormones including an estrane, an androstane,
and a pregnane. b Complex tetracyclic terpenoids that present distinct challenges for chemical synthesis in comparison with relatively simple steroid
hormones. c Design of a concise approach to the enantiospeciﬁc assembly of C19 tetracyclic terpenoid core skeletons 5 and 6
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to that depicted in Fig. 3b. While the factors that contribute to
controlling selectivity in this reaction will be the subject of
ongoing investigations, at this early stage of development it has
been established that the D-ring free hydroxy group (at C16) is
not an essential feature for stereoselection in this unique double-
asymmetric Brønstead acid-mediated ring-closing process. As
illustrated in Fig. 3c, the protected substrate 13 (C16 methyl
ether) can be smoothly converted to a stereodeﬁned tetracycle
(14) in 67% yield, and with similarly high levels of stereocontrol
(ds ≥ 20:1).
Moving forward, a concise sequence of steps was realized to
transform each of the products of double-asymmetric
Friedel–Crafts cyclization to tetracyclic C19 skeletons typical of
steroid hormones. As depicted in Fig. 3d, reductive demethylation
of the enantiodeﬁned syn-isomer ent-12 (prepared from ent-10)
with diisobutylaluminum hydride delivered the corresponding
phenol in high yield26. The designed oxidative rearrangement was
then found to proceed smoothly by treatment with (diacetox-
yiodo)benzene (also referred to as phenyliodine(III) diacetate, or
PIDA)20–22. Presumably acting by way of intermediate 15,
stereospeciﬁc 1,2-methyl shift from C9 to C10 is thought to
deliver a highly stabilized tertiary allylic carbocation 16 that is
terminated by selective loss of a proton from C15, leading to
production of the stereodeﬁned dienone 17—a tetracyclic product
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Fig. 3 Establishment of an asymmetric synthesis of tetracyclic terpenoid skeletons from epichlorohydrin. a Establishing a synthetic route from
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that houses the quaternary centers at C10 and C13 that are seen
in scores of tetracyclic terpenoid targets known to possess an
array of medicinally relevant properties. Notably, the basic
strategy to access 17 is equally effective for preparing the
stereoisomeric tetracycle 20 (Fig. 3e); a compound that possesses
the stereochemical features at C10 and C13 that are common in
limonoids and euphane and tirucallane natural products.
As illustrated in Fig. 3f, this reactivity proved effective for
establishing molecular features that are prominent in the family
of tetracyclic triterpenoids exempliﬁed in Fig. 2a (i.e., euphol and
kansenone). After coupling epoxide 7 to alkyne 21, the resulting
enyne (22) was transformed to hydrindane 23 by alkoxide-
directed metallacycle-mediated annulative cross-coupling. Next,
the double-asymmetric Brønstead acid-promoted cyclization
process proved highly effective for coversion of 23 to the
tetracycle 24 (78% yield; ds ≥ 25:1), and subsequent demethyla-
tion and oxidative rearrangement delivered the tetraene 25 as a
single isomer. Installation of the additional quaternary center at
C14 was then accomplished by capitalizing on the stereochem-
istry at C16 that was previously employed to both enable and
control the regio- and stereochemical course of the metallacycle-
mediated annulation reaction. While a number of strategies may
be considered to achieve such a functionalization process (i.e.,
[2,3] or [3,3]-sigmatropic rearrangement chemistry), hydroxyl-
directed Simmons–Smith cyclopropanation27 was selected for
study here. Gratifyingly, this approach proved highly effective at
establishing the trans-fused hydrindane system featuring adjacent
quaternary centers at C13 and C14. Subsequent treatment with
Co2(CO)8 and H2O resulted in site-selective A-ring enone
reduction28, and furnished the stereodeﬁned intermediate 26 in
69% yield. Finally, a one-pot Birch reduction and alkylation
delivered the fully functionalized and differentiated product 27
that possesses the typical quaternary carbons at C4, C10, C13, and
C14 observed in euphane natural products in 52% yield as a single
stereoisomer.
While further synthetic manipulation of intermediates like 27
was not of interest in this study, the chemical transformations
depicted in Fig. 3 realize a common synthetic pathway for
enantiospeciﬁc access to tetracyclic terpenoid skeletons posses-
sing a variety of stereochemical relationships, as well as spatially
distinct patterns of fully substituted sp3 carbons (quaternary
centers). Furthermore, the highly unsaturated nature of many of
the key intermediates provide opportunities to exploit types of
functionalization chemistry not typically encountered in other
synthetic approaches to such tetracycle formation (i.e., inter-
mediates accessible through biomimetic cation–oleﬁn cycliza-
tion). As such, it is anticipate that this suite of chemistry has the
potential to offer convenient access to synthetic agents in the
broader class that are not easily prepared through other strategies
for de novo synthesis, and that are even wholly incompatible with
efforts that embrace semisynthesis (functionalization of readily
available natural tetracyclic terpenoid starting materials).
Discovery of estrogen receptor beta (ERβ) agonists. With
recognition that the chemical pathway established proceeds by way of
structurally unique partially aromatic tetracycles in the estrane series
(i.e., 11 and 12; Fig. 3a), attention was directed toward investigating
the potential value of these species outside of their future role as
synthetic intermediates in natural product and function-oriented
synthesis campaigns. In fact, relatively few natural tetracyclic terpe-
noids have the core structure seen in the intermediates accessed here
(after double-asymmetric Friedel–Crafts cyclization), and none have
the combination of substitution and unsaturation seen in 11 and 12.
That said, it was appreciated that partially aromatic synthetic ster-
oidal systems have been described as modulators of estrogen recep-
tors, ERα and ERβ (vide infra).
In particular, the estrogen receptor beta (ERβ) is a nuclear
hormone receptor that was discovered in 1996 and has been
recognized as a potentially important pharmaceutical target29,30.
This nuclear hormone receptor is distinct from ERα; it is not
expressed in the pituitary and has little role in the proliferation of
the mammary gland or endometrium30. Agonism of ERβ is of
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great current pharmaceutical interest due to a variety of
observations that include decreasing survival of p53-defective
cancer cells by imparing G2/M checkpoint signaling31, playing a
role as a tumor suppressor of epithelial ovarian cancer32 and of
gliomas33, reducing invasiveness of triple-negative breast cancer
cells34, inducing cell death in acute myeloid leukemia35, and
decreasing proliferation of ovarian cancer cells36. Notably, ERβ
has also been considered as a target of potential value for
neuroprotection37, diabetes38, inﬂammation and pain39–42.
Being aware that 9α-substituted estratrienes have been
described as selectively active estrogens43, we sought to
investigate the ER-modulating properties associated with some
molecules now readily available from the chemical advances
described herein. Notably, unlike most explorations into the
bioactivity of steroidal systems, the synthetic chemistry estab-
lished here provides straightforward access to both enantiomeric
series, and delivers unique compositions of matter whose
additional unsaturation at C8 offers unique physical properties
(i.e., altered solubility and rigidity) along with subtle perturbation
of three dimensional molecular structure in comparison to related
saturated variants.
As illustrated in Fig. 4a, the enantiomeric tetracycles 28 and
ent-28, each prepared in only six steps from epichlorohydrin
(as previously presented in Fig. 3a), were found to be potent
and selective agonists of ERβ in an in vitro, bioluminescence
cellular-reporter assay. Here, 17β-estradiol was used as a
control, as it is appreciated to be a potent agonist of both
ERα and ERβ. The enantiomer of interest for the de novo
synthesis of euphane- and tirucallane-based natural products
(28) was found to induce partial agonism of ERβ with an EC50
of 1.9 nM and clear selectivity for ERβ vs. ERα in comparison
with 17β-estradiol. Speaking to the great impact that absolute
stereochemistry can have on the biological and/or medicinal
properties of organic molecules, the enantiomeric tetracycle
(ent-28) proved to be markedly more potent and selective than
its antipode — it was found to be a highly potent full agonist of
ERβ with an EC50 value of 0.05 nM, and a superior selectivity
proﬁle over ERα. To our knowledge, these novel compositions
of matter have unprecedented properties as selective agonists of
ERβ33,36,37,41,42,44–49, while offering a validated and pharma-
ceutically relevant backbone on which to build selective
clinically valuable agents.
Regulation of ERβ in prostate cancer cells. Prostatic epitheleal
hyperplasia is evident in mice lacking ERβ50, suggesting that ERβ
may play a role in limiting proliferation in the prostate. These
data suggest that pharmacological activation of ERβ may be
useful in treatment of prostate cancer. The DU-145 prostate
cancer cell line only expresses ERβ51, and can be used as a model
to examine the activation of ERβ in the absence of any potential
confounding signal driven by ERα. Alkaline phosphatase (ALP)
expression is induced in an ER-dependent manner, and has been
used to characterize the activity of synthetic ER agonists and
antagonists52.
In order to examine the ability of 28 and ent-28 to activate ERβ
in the context of a cell line expressing endogenous ERβ, DU-145
cells were treated for 24 h with either 17β-estradiol, 28, or ent-28,
and ALP activity derived from the cells was examined. As shown
in Fig. 4b, 17β-estradiol was effective in inducing ALP activity as
expected. In addition, both 28 and ent-28 were effective at
inducing ALP to levels comparable to 17β-estradiol. These data
are consistent with 28 and ent-28 functioning as ERβ agonists.
Inhibition of glioblastoma in vitro. Glioblastomas are the most
malignant and lethal brain tumors, with a median survival rate of
14 months and a 5-year survival rate of less than 10%. Despite
attempts to combine surgery, radiation, and chemotherapeutics,
gliomas recur in more than 90% of cases. This is primarily due to
gliomas being heterogeneous tumors with each individual tumor
expressing distinct patterns of oncogenes and mutated tumor-
suppressor genes, thus making molecular characterization and
targeted treatment challenging. However, elevated levels of ERβ
expression have been observed in most glioblastomas examined
to date33,53. ERβ is an established tumor suppressor in several
cancers; higher expression of ERβ is correlated to a better prog-
nosis, and ERβ agonists induce apoptosis53–55. Nevertheless,
despite the tumor suppressive role of ERβ, 17β-estradiol (a potent
but unselective agonist of ERα and ERβ) is not used as a therapy
against gliomas because long-term treatment can result in cancers
of the female reproductive system and prostate cancer in
men56,57. In comparison with 17β-estradiol, 28 and ent-2858 have
a unique proﬁle for selective agonism of ERβ (Fig. 4a). Further-
more, as data from both the ERβ speciﬁc in vitro bioluminescence
reporter assay (Fig. 4a) and the ERβ only expressing prostate
cancer line DU-145 (Fig. 4b) established that 28 and ent-28 are
ERβ agonists, we hypothesized that targeting ERβ with 28 or ent-
28 in gliomas may establish a novel and highly efﬁcacious therapy
against this deadly brain tumor.
To determine the biological effect of 28 and ent-28, human
glioblastoma-derived cell lines U251 and U87 were treated with
varying concentrations of 28, ent-28, temazolomide (TMZ; a
standard of care chemotherapeutic agent), or vehicle-toxicity
control, dimethylsulfoxide (DMSO) used at ﬁnal volumes that
were identical to those used to attain all concentrations tested of
28 and ent-28. Remarkably, 28 and ent-28 demonstrated
inhibition of glioma cell growth (IC50) at a 50-fold lower
concentration when compared with TMZ after 24 h (Fig. 5a).
Furthermore, when cell viability was assessed every 24h for
5 days, we observed that 28 and ent-28 reduced viability and the
resulting proliferation of glioblastoma lines in a dose-dependent
manner compared with cells that were incubated with TMZ or
DMSO (Fig. 5a; Supplementary Fig. 1). More importantly, cell
viability of human neural stem cells as well as human astrocytes
was not affected at the equivalent concentration, demonstrating
that both 28 and ent-28 have glioma-speciﬁc cytotoxic activity
(Fig. 5; Supplementary Figs. 2, 3). This was further conﬁrmed by
MTT cell-viability assays wherein 28 and ent-28 treatment sig-
niﬁcantly reduced the growth of glioblastoma cell lines in a dose-
dependent manner (Supplementary Figs. 4, 5).
In order to elucidate the mechanism of this cell death,
glioblastoma cells treated for 24 h with 28, ent-28, TMZ, or
DMSO control were analyzed for early- and late-apoptosis
markers (Annexin V and 7-Aminoactinomycin D) by FACS
analyses. These experiments revealed a sevenfold higher induc-
tion of apoptosis in U251 and U87 cells treated with 28 or ent-28
compared with cells treated with either TMZ or DMSO controls
(Fig. 5c; Supplementary Fig. 6). In addition, over a period of
5 days, morphological changes in U251 and U87 cells treated with
28 and ent-28 were tracked using the Incucyte live cell imaging
system. Increased loss of adherence and cellular integrity were
observed following treatment of U251 and U87 with 28 and ent-
28, correlating with the decreased viability and increased cell
death observed previously; similar behavior was not seen with
human neural stem cells as well as human astrocytes (Fig. 5d;
Supplementary Figs. 2, 3).
Collectively, these investigations indicate that 28 and ent-28
each reduce cell viability, decrease survival, and induce apoptosis
selectively in glioblastoma cells. This proﬁle supports further
investigation of the novel enantiomeric tetracycles 28 and ent-28
as therapeutic agents against gliomas that are resistant to all
currently available treatment modalities.
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In conclusion, the rich and diverse collection of tetracyclic
terpenoids has served as motivation for the design and execution
of a new chemical synthesis platform capable of constructing
central motifs of their carbocyclic backbones in just a handful of
steps from an inexpensive and readily available chiral starting
material (epichlorohydrin). The process comprises a modern
metallacycle-mediated annulative cross-coupling, a C9–C10 bond-
forming process through a double-asymmetric Friedel–Crafts
cyclization, and an oxidative rearrangement reaction. It has been
shown that this sequence of molecular transformations can be
used to deliver a variety of stereodeﬁned systems that contain
quaternary centers at C9, C10, C13, and C14, and that
compositions of matter encountered in this chemical synthesis
pathway are potent agonists of ERβ and have selective anticancer
properties against glioblastoma. While it is anticipated that
molecules now accessible from this chemical advance will be a
rich source of bioactive leads for drug discovery and development
across a diverse therapeutic landscape, it is already clear that the
science described allows for de novo synthesis of either
enantiomer of the tetracyclic skeletons resident in a wide variety
of terpenoids with ease, rendering unique opportunities for
medicinal exploration viable. Efforts directed at advancing this
collection of advances in preparative organic chemistry to address
challenges in natural product synthesis and medicinal science are
of great current and future interest.
Methods
Synthesis of enyne 22. To a stirring solution of 21 (5.4 g, 31 mmol, 2.0 equiv) in
90 mL of THF at −78 °C under N2 atmosphere was added n-BuLi (2.5 M in hex-
anes, 10 mL, 25 mmol, 1.6 equiv) dropwise over 3 min, and the resulting mixture
was stirred for 30 min at the same temperature. After the speciﬁed period of time,
BF3•OEt2 (4.0 g, 28 mmol, 1.8 equiv) was added dropwise to the reaction mixture
followed by 7 (1.5 g, 15 mmol, 1.0 equiv). The resulting mixture was stirred at −78
°C under N2 atmosphere for 55 min, and then quenched with 50 mL of saturated
solution of NaHCO3 at the same temperature. The resulting biphasic solution was
warmed to room temperature, and then further diluted with 50 mL of ethyl acetate.
The organic layer was separated, dried over Na2SO4, ﬁltered, and then the ﬁltrate
was concentrated in vacuo. SiO2 ﬂash column chromatography afforded the title
compound 22 as a clear oil (3.9 g, 91%); Spectral Data for 22: 1H NMR (600MHz,
Chloroform-d): δ 7.13 (t, J= 7.9 Hz, 1H), 6.85 (d, J= 1.1 Hz, 1H), 6.76 (d, J= 1.1
Hz, 1H), 4.92 – 4.86 (m, 1H), 4.86 – 4.80 (m, 1H), 3.89 – 3.84 (m, 1H), 3.83 (s, 3H),
2.87 (t, J= 7.7 Hz, 2H), 2.47 (tt, J= 7.6, 2.4 Hz, 2H), 2.43 – 2.33 (m, 2H), 2.29 (ddd,
J= 13.9, 4.9, 1.2 Hz, 1H), 2.25 – 2.18 (m, 4H), 2.16 (s, 1H), 1.79 (s, 3H); 13C NMR
(150MHz, chloroform-d): δ 157.7, 142.4, 140.1, 126.0, 124.5, 121.4, 113.3, 108.3,
82.3, 76.8, 67.8, 55.4, 44.7, 32.9, 27.2, 22.5, 19.8, 11.2; IR (thin ﬁlm): 3441, 2933,
2835, 1585, 1463, 1439, 1258, 1101 cm;−1 HRMS (ESI–TOF) calculated for
C18H25O2 [M+H]+ 273.1855, found 273.1855;½α22D ¼ 1:1 (0.05, CHCl3).
Synthesis of hydrindane 23. To a stirring solution of 1-(trimethylsilyl)propyne
(3) (4.5 g, 40 mmol, 3.1 equiv) and Ti(Oi-Pr)4 (11 g, 38 mmol, 3.0 equiv) in 200 mL
of anhydrous toluene at −78 °C under N2 atmosphere was added n-BuLi (2.3 M in
hexanes, 33 mL, 76 mmol, 5.9 equiv) dropwise. After the addition, the cooling bath
was removed, and the resulting dark brown mixture was warmed to rt, and then
further warmed to 50 °C. The reaction mixture was stirred for 50 min at the same
temperature without a reﬂux condenser, and then cooled to rt. A separate round
bottom ﬂask charged with a solution of 22 (3.5 g, 13 mmol, 1.0 equiv) in 50 mL of
anhydrous toluene at −78 °C under N2 atmosphere was added n-BuLi (2.3 M in
hexanes, 5.5 mL, 13 mmol, 1.0 equiv) dropwise. The resulting solution was warmed
to rt, cannulated into the above dark brown mixture, and then stirred overnight at
rt under N2 atmosphere (approx. 12 h). After this period, 100 mL of saturated
solution of NH4Cl was added, and the mixture was further diluted with 100 mL of
ethyl acetate. The organic layer was separated, and the aqueous layer was extracted
with 250 mL × 2 ethyl acetate. The combined organic layers were dried with
Na2SO4, ﬁltered, and the ﬁltrate was concentrated in vacuo. SiO2 ﬂash column
chromatography afforded the title compound 23 as a yellow oil (2.6 g, 53% isolated
yield); Spectral Data for 23: 1H NMR (500MHz, chloroform-d): δ 7.07 (t, J= 7.9
Hz, 1H), 6.71 (d, J= 7.9 Hz, 2H), 4.41 – 4.31 (m, 1H), 3.81 (s, 3H), 2.73 – 2.62 (m,
2H), 2.57 (dt, J= 13.5, 8.0 Hz, 1H), 2.44 – 2.37 (m, 1H), 2.35 – 2.27
(m, 1H), 2.20 (s, 3H), 2.16 (d, J= 15.5 Hz, 1H), 2.05 – 1.97 (m, 3H), 1.95 (app d, J
= 2.7 Hz, 3H), 1.40 (dd, J= 12.4, 7.5 Hz, 1H), 1.20 (s, 1H), 0.79 (s, 3H), 0.16 (s,
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Fig. 5 Ent-28 and 28 inhibit proliferation and induce apoptosis in glioblastoma cell lines. a IC50 at 24 h: dose-dependent growth inhibition of U251 and U87
cells treated with 28, ent-28, TMZ, and vehicle control DMSO (n= 4). b Cell proliferation over 96 h: viable cell counts of U251 and U87 cells treated with
28, ent-28, TMZ, and vehicle control DMSO determined every 24 h for 96 h (n= 4). c Apoptosis at 24 h: ﬂow-cytometric analysis of U251 and U87 co-
stained with Annexin V-FITC/7-AAD after treatment with 28, ent-28, TMZ, and vehicle control DMSO (n= 4). d Morphological analyses at 24 h: phase-
contrast images using Incucyte for live cell tracking of U251 and U87 cells in response to treatment with 28, ent-28, TMZ, and vehicle control DMSO. Live
cells were tracked and imaged for 96 h (data not shown). Scale bar= 300 μm. All data in this ﬁgure are representative of four independent experiments,
and four replicates of each treatment condition were analyzed per experiment. Mean ± s.d. of quadruplicates from one experiment are presented on the line
plots. Source data are provided as a Source Data File
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9H); 13C NMR (150MHz, Chloroform-d): δ 157.8, 144.4, 141.8, 141.3, 129.5, 128.5,
126.0, 124.8, 122.3, 108.0, 72.1, 55.7, 51.3, 41.6, 39.4, 38.5, 33.2, 30.5, 21.4, 19.2,
11.4, 0.2; IR (thin ﬁlm): 3349, 2950, 1585, 1465, 14371102, 1063, 1063, 835 cm;−1
HRMS (ESI–TOF): calculated for C24H37O2Si [M+H]+ 385.2563, found 385.2563;
½α22D ¼ 39:3 (c 0.014, CHCl3).
Synthesis of tetracycle 24. To a stirring suspension of (S)-BINOL (6.1 g, 21
mmol, 5.3 equiv) in 200 mL of dichloromethane at −78 °C under N2 atmosphere
was added a solution of SnCl4 (1.0 M in dichloromethane, 21 mL, 21 mmol, 5.3
equiv) dropwise using syringe. The resulting mixture was stirred for 29 min at −78
°C, and then a solution of 23 (1.5 g, 4.0 mmol, 1.0 equiv) in 80 mL of dichlor-
omethane was added dropwise via cannula transfer. The resulting mixture was
stirred for 1.3 hr at −78 °C, and then warmed to rt over 30 min. The reaction was
judged to be complete by TLC-analysis, and 100 mL of saturated solution of NH4Cl
was added. The organic layer was separated, washed with 200 mL 5% solution of
NaOH. The aqueous layer was further extracted with 200 mL of dichloromethane.
The combined organic layers were dried over Na2SO4, ﬁltered, and the ﬁltrate was
concentrated in vacuo. SiO2 ﬂash column chromatography afforded the title
compound 24 as an amorphous white solid (0.96 g, 78%); Spectral Data for 24: 1H
NMR (600MHz, chloroform-d) δ 7.14 (d, J= 8.7 Hz, 1H), 6.77 (d, J= 8.7 Hz, 1H),
4.63 – 4.57 (m, 1H), 3.80 (s, 3H), 2.92 (dd, J= 14.5, 5.7 Hz, 1H), 2.85 (dd, J= 16.7,
8.7 Hz, 1H), 2.54 – 2.46 (m, 2H), 2.38 – 2.27 (m, 2H), 2.16 (dd, J= 11.9, 6.7 Hz,
1H), 2.13 – 2.05 (m, 4H), 1.85 – 1.78 (m, 1H), 1.71 (dt, J= 9.3, 3.1 Hz, 2H), 1.57 (s,
1H), 1.38 – 1.32 (m, 4H), 0.89 (s, 3H); 13C NMR (150MHz, chloroform-d) δ 155.0,
140.4, 135.9, 131.8, 124.1, 123.7, 108.7, 71.7, 55.7, 52.1, 41.5, 38.3, 37.7, 35.0, 33.6,
31.6, 29.7, 25.9, 24.8, 11.5; IR (thin ﬁlm): 3344, 2934, 2856, 2833, 1595, 1482, 1263,
1101, 755; HRMS (ESI–TOF): calculated for C21H29O2 [M+H]+ 313.2168, found
313.2162; ½α22D ¼ 169:71 (c 0.0046, CHCl3).
Synthesis of enone 25. To a stirring solution of 24 (1.5 g, 4.7 mmol, 1.0 equiv) in
50 mL of anhydrous toluene at rt under N2 atmosphere was added DIBAL-H (1.0
M in hexanes, 47 mL, 47 mmol, 10 equiv). The resulting mixture was warmed to
100 °C, reﬂuxed overnight (approx. 16 h), and then cooled to rt. Small chunks of ice
was slowly added, and the resulting mixture was diluted with 200 mL water, 10 mL
1M solution of HCl, and 250 mL of ethyl acetate. The separated organic layer was
dried with Na2SO4, ﬁltered, and concentrated in vacuo to afford 1.41 g of the crude
product as an amorphous yellow solid. The crude product (1.4 g) at 0 °C under N2
atmosphere was added with 50 mL of HFIP followed by PIDA (1.4 g, 4.3 mmol).
The resulting mixture was stirred for 1 min at 0 °C (PIDA was fully dissolved at this
point), and then 30 mL of saturated solution of NaHCO3 was added. HFIP was
removed in vacuo, and the remaining aqueous mixture was extracted with 100
mL × 3 ethyl acetate. The combined organic layers were dried over Na2SO4, ﬁltered,
and the ﬁltrate was concentrated in vacuo. The crude product was puriﬁed with
SiO2 ﬂash column chromatography to afford the title compound 25 as an amor-
phous white solid (0.76 g, 54% over 2 steps). Spectral data for 25: 1H NMR (500
MHz, chloroform-d) δ 7.14 (d, J= 10.1 Hz, 1H), 6.28 (d, J= 10.1 Hz, 1H), 5.50 (s,
1H), 5.11 – 5.02 (m, 1H), 2.97 (ddd, J= 13.0, 6.0, 1.7 Hz, 1H), 2.71 (ddt, J= 16.5,
6.3, 2.0 Hz, 1H), 2.53 – 2.39 (m, 2H), 2.34 (app dd, J= 12.1, 6.5 Hz, 2H), 2.18
(ddtd, J= 18.6, 10.3, 4.1, 2.0 Hz, 1H), 1.95 (s, 3H), 1.82 (ddd, J= 12.6, 5.0, 1.4 Hz,
1H), 1.64 (s, 1H), 1.57 (td, J= 12.4, 5.6 Hz, 2H), 1.45 (s, 3H), 1.40 (dd, J= 12.1, 7.6
Hz, 1H), 0.88 (s, 3H); 13C NMR (150MHz, chloroform-d) δ 185.4, 159.4, 151.9,
149.9, 137.9, 128.3, 127.6, 125.4, 124.3, 76.6, 51.7, 44.8, 43.3, 36.2, 28.8, 28.4, 25.4,
24.7, 23.6, 10.5; IR (thin ﬁlm): 3404, 2923, 2851, 1659, 1625,1607, 1449, 1051, 833,
753 cm;−1 HRMS (ESI–TOF): calculated for C20H25O2[M+H]+ 297.1855, found
297.1856; ½α22D ¼ þ156:27 (c 0.0032, CHCl3).
Synthesis of tetracycle 26. To a stirring solution of S7 (2.9 g, 9.3 mmol, 1.0 equiv)
and water (3.6 g, 200 mmol, 22 equiv) in 190 mL dimethoxyethane was added
Co2(CO)8 (8.0 g, 23 mmol, 2.5 equiv). The resulting mixture was reﬂuxed for 3 h at
90 °C, and for 1 h at 100 °C. The reaction mixture was cooled to rt, and another
portion of Co2(CO)8 (3.2 g, 9.4 mmol, 1.0 equiv) was added. The reaction mixture
was warmed to 90 °C again, continued to reﬂux for 1.7 h, and then cooled to rt. The
resulting mixture was passed through a pad of silica gel using 850 mL of ethyl
acetate, 100 mL 5% methanol/95% ethyl acetate, and 10% methanol/90% ethyl
aceate as the eluent, and then the ﬁltrate was concentrated in vacuo. The crude
product was puriﬁed by dry column vacuum chromatography1 using 200 mL of
dichloromethane and then a gradient elution (20% ethyl acetate/80% hexanes to
50% ethyl aceate/50% hexanes, 5% increase in ethyl acetate/ fraction, 500 mL/
fraction) to afford 2.02 g of the title compound 26 as an amourphous white solid
(69% yield). Spectral data for 26: 1H NMR (600MHz, chloroform-d) δ 4.63 (td,
J= 7.7, 4.0 Hz, 1H), 2.72 (ddd, J= 12.9, 4.9, 2.3 Hz, 1H), 2.51 (ddd, J= 17.3, 14.7,
5.1 Hz, 1H), 2.42 (ddd, J= 17.3, 4.8, 2.7 Hz, 1H), 2.24 – 2.07 (m, 4H), 1.94 (dt, J=
7.4, 3.5 Hz, 1H), 1.86 – 1.66 (m, 7H), 1.65 – 1.58 (m, 3H), 1.30 (s, 3H), 0.96 (dd,
J= 12.5, 8.7 Hz, 1H), 0.88 (s, 3H), 0.82 (dd, J= 5.1, 3.1 Hz, 1H), 0.38 (dd, J= 7.5,
5.2 Hz, 1H); 13C NMR (150MHz, chloroform-d) δ 198.7, 163.5, 133.3, 129.5, 127.4,
73.7, 41.4, 40.0, 38.9, 37.7, 34.0, 33.4, 31.6, 26.33, 26.26, 26.1, 23.4, 23.0, 21.7, 10.8,
10.1; IR (thin ﬁlm): 3399, 2922, 1660, 1613, 1450, 1373, 1357, 1332, 1074, 1054,
1025 cm;−1 HRMS: calculated for C21H29O2 [M+H]+ 313.2168, found 313.2164;
½α22D ¼ þ252:2 (c 0.021, CHCl3).
Synthesis of tetracycle 27. To a stirring blue solution of Li (20 mg, 2.9 mmol, 10
equiv) in 10 mL NH3 (l) at −78 °C under N2 atmosphere was added a solution of
26 (89 mg, 0.28 mmol, 1.0 equiv) in 2 mL THF dropwise. The resulting mixture was
stirred for 15 min at −78 °C, warmed to −35 °C, and then stirred for 50 min while
maintaining the cold bath temperature between −35 °C and −25 °C. After this
period, the reaction mixture was cooled to −78 °C, and then MeI (0.81 g, 5.7 mmol,
20 equiv) was added dropwise. The cold bath was removed, and NH3 (l) was
evaporated under a stream of N2 over 30 min. In total, 5 -mL saturated solution of
NH4Cl was added, and the resulting mixture was further diluted with 10 mL of
ethyl acetate and 5 mL of water. The organic layer was separated, and the aqueous
layer was extracted with 25 mL × 2 ethyl acetate. The combined organic layers were
dried with Na2SO4, ﬁltered, and the ﬁltrate was concentrated in vacuo. SiO2 ﬂash
column chromatography afforded the title compound 27 as a pale yellow ﬁlm (48
mg, 52%); Spectral data for 27: 1H NMR (500MHz, chloroform-d) δ 4.69 – 4.59
(m, 1H), 2.57 (ddd, J= 15.9, 10.4, 7.5 Hz, 1H), 2.46 (ddd, J= 15.9, 7.5, 3.8 Hz, 1H),
2.20 – 2.07 (m, 2H), 2.07 – 2.00 (m, 1H), 1.94 (dt, J= 7.4, 3.5 Hz, 1H), 1.81 – 1.71
(m, 1H), 1.71 – 1.56 (m, 7H), 1.45 (dq, J= 18.4, 6.2 Hz, 1H), 1.36 (br s, 1H), 1.09 (s,
3H), 1.08 (s, 3H), 1.05 (s, 3H), 0.97 – 0.90 (m, 4H), 0.75 (dd, J= 5.0, 3.1 Hz, 1H),
0.32 (dd, J= 7.5, 5.0 Hz, 1H); 13C NMR (150MHz, chloroform-d) δ 217.9, 134.8,
128.0, 73.9, 51.7, 47.4, 41.7, 39.1, 38.1, 37.5, 35.5, 34.6, 31.9, 26.79, 26.76, 26.3, 22.9,
21.9, 21.3, 19.9, 19.7, 10.2; IR (thin ﬁlm): 3392, 2950, 2924, 1704, 1473, 1457, 1383,
1058, 1020, 754 cm;−1 HRMS: calculated for C22H31O2 [M–H]+ 327.2324, found
327.2325; ½α22D ¼ þ82:0 (c 0.0065, CHCl3).
Cell lines and reagents. Human GBM cells U87, U251 were obtained from
American Type Culture Collection (ATCC, Manassas, VA) and were cultured as
per ATCC guidelines. Adult human neural progenitor cells were a generous gift
from Drs. Steindler & Tong, Tufts University. Human astrocytes were obtained
from ThermoFisher (Catalog number: N7805100). Following standard laboratory
protocols, all study model cells utilized were determined to be free of mycoplasma
contamination, and were conﬁrmed by using MycoSEQ™ Mycoplasma Detection
Kit, with Discriminatory Positive Control (ThermoFisher; Catalog number:
4460623).
Cell survival/proliferation and IC50 assays. To determine growth inhibition,
U87 and U251 cells plated in 96-well plates for 24 h were treated with varying doses
of 28, ent-28, TMZ or vehicle control DMSO for 96 h. Cells were counted every 24
h after initiating treatment. This was done after the wells were ﬁrst washed with
PBS and the remaining adherent, viable cells in each well were trypsinized and
counted using a hemocytometer following trypan blue exclusion. The data were
normalized to untreated cell counts obtained from cells prior to initiating treat-
ment at 0 h. The data were analyzed from four replicates and each experiment was
repeated at least three times.
Flow-cytometric analysis of apoptotic cell death. U87 and U251 cells were
seeded in six-well plates (300,000 cells/well) 24 h prior to treatment. Each well was
treated with various concentrations of 28, ent-28, TMZ, or vehicle control DMSO
for 24 h. DMSO was used as a negative control. The cells were then washed and
stained with Annexin V-FITC and 7-AAD (BioLegend), according to the manu-
facturer’s instructions, and were analyzed on a MACSQuant® Analyzer 10 (Mil-
tenyi Biotec Inc.). Staurosporine (STS) treatment at 1 μM served as a positive
control for Annexin V staining and DMSO was used as a negative control. The ﬁles
were converted to FCS compatible format and analyzed using FlowJo analysis
software (Treestar). The quantitative analysis of the percentage of apoptotic cells
was reported from three independent experiments.
Cell morphology studies of 28 and ent-28 versus TMZ. U87 and U251 cell lines,
adult human neural progenitor cells (a generous gift from Drs. Steindler & Tong,
Tufts University), and human astrocytes (ThermoFisher) were seeded in a 96-well
plate format with a density of 1000 cells per well and incubated for 24 h before
treatment. Each well was then supplemented with fresh media containing various
concentrations of 28, ent-28, TMZ, or vehicle control DMSO. Phase-contrast
images at ×10 magniﬁcation were acquired using the IncuCyte® Live-Cell Imaging
System (Essen Instruments). Each well was imaged four times every 24 h over
5 days and image-based analysis of cell morphology was carried out using the
Incucyte Software. The results are representative of four independent experiments.
Cell-viability assays. Cell viability after treatment in quadruplicate in 96-well
plates was detected by the MTT assay. U87 and U251 cells plated as described
above were treated with 28, ent-28, and TMZ with a DMSO control over 96 h.
Every 24 h, the medium was removed and 20 μL of MTT (5 mg/mL) was added for
4 h. After removing supernatant, 100 μL of DMSO was added to resolve formazan
crystals, and the plates were measured at 595 nm with a SpectraMax® i3x micro-
plate reader (Molecular Devices, Sunnyvale, CA, USA). The data were collected
using Softmax Pro 6.5.1 software (Molecular Devices). The results are repre-
sentative of at least three independent experiments.
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Evaluation of 28 and ent-28 in DU-145 prostate cancer cells. Human DU-145
prostate cancer cells were plated at a density of 10,000 cells per well (96-well plates)
in RPMI+ 10% fetal bovine serum (FBS) without phenol red. Two days after
plating, cells were treated with compounds (5 µM) for 24 h in RPMI+ 10%
charcoal-stripped FBS without phenol red. ALP activity was determined using the
ThermoFisher Scinetiﬁc 1-step PNPP assay according to the manufacturer’s
protocol.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All relevant data are available from the authors, and are included with the manuscript in
the accompanying Supplementary Information. These include characterization for all
new compositions of matter (organic molecules), as well as copies of relevant NMR
spectra, experimental procedures, and supplemental ﬁgures associated with the biological
evaluation of 28 and ent-28 (data associated with these evaluations are provided in the
Manuscript and Supplementary Information; raw data is available upon request). X-ray
crystallographic coordinates for compound 24 have been deposited at the Cambridge
Crystallographic Data Centre (CCDC), under deposition number CCDC 1897943. These
data can be obtained free of charge from The Cambridge Crystallographic Data Centre
via www.cdc.cam.ac.uk/data_request/cif. The raw data underlying Figs. 4 and 5, as well as
Supplementary Figs. 1, 2, 4, and 5 are provided in a Source Data File.
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